Skip to main content
Erschienen in: Die Ophthalmologie 12/2021

03.11.2021 | Trabekulektomie | Einführung zum Thema

Schlüsselstudien zum Glaukom der letzten 10 Jahre

verfasst von: Dr. Karl Mercieca, MD PGCMEd FRCOphth FEBOS-GL

Erschienen in: Die Ophthalmologie | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Auszug

Die Möglichkeiten zur Diagnose und Behandlung des Glaukoms haben sich in den letzten 10 Jahren durch neue bildgebende Verfahren, pharmakologische Behandlungen und neuartige Operationsmethoden exponentiell erweitert. Aufgrund dieser umfangreichen Auswahl kann es ziemlich schwierig sein zu entscheiden, welche Option für jeden einzelnen Patienten am besten geeignet ist. Dies gilt umso mehr angesichts der umfangreichen Informationsflut, die von Herstellern, Forschern und Kollegen veröffentlicht und präsentiert wird. Mit diesem Leitthema haben wir uns daher entschieden, einige der bedeutenden wegweisenden Glaukomstudien, die in den letzten 10 Jahren veröffentlicht wurden, vorzustellen. Damit wollen wir die Anwendung evidenzbasierter Medizin bei der Planung von Untersuchungen und Behandlungen unserer Patienten fördern. …
Literatur
1.
Zurück zum Zitat Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121:2081–2090CrossRef Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121:2081–2090CrossRef
2.
Zurück zum Zitat Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120(6):701–713CrossRef Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120(6):701–713CrossRef
3.
Zurück zum Zitat Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA (2002) The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120(6):714–720CrossRef Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA (2002) The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120(6):714–720CrossRef
4.
Zurück zum Zitat Budenz DL, Huecker JB, Gedde SJ, Gordon M, Kass M, Ocular Hypertension Treatment Study Group. (2017) Thirteen-year follow-up of optic disc hemorrhages in the ocular hypertension treatment study. Am J Ophthalmol 174:126–133CrossRef Budenz DL, Huecker JB, Gedde SJ, Gordon M, Kass M, Ocular Hypertension Treatment Study Group. (2017) Thirteen-year follow-up of optic disc hemorrhages in the ocular hypertension treatment study. Am J Ophthalmol 174:126–133CrossRef
5.
Zurück zum Zitat Cousins X, Chou JC, Shen LQ, Gordon MO, Kass MA, Ritch R, Pasquale LR (2020) Densitometric profiles of optic disc hemorrhages in the ocular hypertension treatment study. Am J Ophthalmol 217:10–19CrossRef Cousins X, Chou JC, Shen LQ, Gordon MO, Kass MA, Ritch R, Pasquale LR (2020) Densitometric profiles of optic disc hemorrhages in the ocular hypertension treatment study. Am J Ophthalmol 217:10–19CrossRef
6.
Zurück zum Zitat Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz NK, Investigators CS (2009) Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology 116:200–207CrossRef Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz NK, Investigators CS (2009) Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology 116:200–207CrossRef
7.
Zurück zum Zitat Musch DC, Lichter PR, Guire KE, Standardi CL (1999) The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 106(4):653–662CrossRef Musch DC, Lichter PR, Guire KE, Standardi CL (1999) The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 106(4):653–662CrossRef
8.
Zurück zum Zitat Feiner L, Piltz-Seymour JR (2003) Collaborative Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthalmol 14(2):106–111CrossRef Feiner L, Piltz-Seymour JR (2003) Collaborative Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthalmol 14(2):106–111CrossRef
9.
Zurück zum Zitat Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC (2020) The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology 127(4):477–483CrossRef Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC (2020) The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology 127(4):477–483CrossRef
10.
Zurück zum Zitat Glaucoma Laser Trial Research Group (1990) The glaucoma laser trial (GLT): 2. Results of argon laser trabeculoplasty vs. topical medicines. Ophthalmology 97(11):1403–1413CrossRef Glaucoma Laser Trial Research Group (1990) The glaucoma laser trial (GLT): 2. Results of argon laser trabeculoplasty vs. topical medicines. Ophthalmology 97(11):1403–1413CrossRef
11.
Zurück zum Zitat Glaucoma Laser Trial Research Group (1995) The glaucoma laser trial (GLT) and glaucoma laser trial follow up study: 7. Results. Am J Ophthalmol 120(6):718–731CrossRef Glaucoma Laser Trial Research Group (1995) The glaucoma laser trial (GLT) and glaucoma laser trial follow up study: 7. Results. Am J Ophthalmol 120(6):718–731CrossRef
12.
Zurück zum Zitat AGIS Investigators (1998) Advanced Glaucoma Intervention Study (AGIS): 4. comparison of treatment outcomes within race: 7 yr results. Ophthalmology 105:1146–1164CrossRef AGIS Investigators (1998) Advanced Glaucoma Intervention Study (AGIS): 4. comparison of treatment outcomes within race: 7 yr results. Ophthalmology 105:1146–1164CrossRef
13.
Zurück zum Zitat Garway-Heath DF, Lascaratos G, Bunce C, Crabb DP, Russell RA, Shah A, United Kingdom Glaucoma Treatment Study Investigators (2013) The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical trial: design and methodology. Ophthalmology 120(1):68–76CrossRef Garway-Heath DF, Lascaratos G, Bunce C, Crabb DP, Russell RA, Shah A, United Kingdom Glaucoma Treatment Study Investigators (2013) The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical trial: design and methodology. Ophthalmology 120(1):68–76CrossRef
14.
Zurück zum Zitat Jones L, Garway-Heath DF, Azuaro-Blanco A, Crabb DP (2019) Are patient self-reported outcome measures sensitive enough to be used as end points in clinical trials?: evidence from the United Kingdom glaucoma treatment study. Ophthalmology 126:682–689CrossRef Jones L, Garway-Heath DF, Azuaro-Blanco A, Crabb DP (2019) Are patient self-reported outcome measures sensitive enough to be used as end points in clinical trials?: evidence from the United Kingdom glaucoma treatment study. Ophthalmology 126:682–689CrossRef
15.
Zurück zum Zitat Founti P, Bunce C, Khawaja AP, Doré CJ, Mohamed-Noriega J, Garway-Heath DF, United Kingdom Glaucoma Treatment Study Group (2020) Risk factors for visual field deterioration in the united kingdom glaucoma treatment study. Ophthalmology 127(12):1642–1651CrossRef Founti P, Bunce C, Khawaja AP, Doré CJ, Mohamed-Noriega J, Garway-Heath DF, United Kingdom Glaucoma Treatment Study Group (2020) Risk factors for visual field deterioration in the united kingdom glaucoma treatment study. Ophthalmology 127(12):1642–1651CrossRef
16.
Zurück zum Zitat Azuara-Blanco A, Banister K, Boachie C, McMeekin P, Gray J, Burr J, Bourne R, Garway-Heath D, Batterbury M, Hernandez R, McPherson G, Ramsay C, Cook J (2016) Automated imaging technologies for the diagnosis of glaucoma: a comparative diagnostic study for the evaluation of the diagnostic accuracy, performance as triage tests and cost-effectiveness (GATE study). Health Technol Assess 20:8CrossRef Azuara-Blanco A, Banister K, Boachie C, McMeekin P, Gray J, Burr J, Bourne R, Garway-Heath D, Batterbury M, Hernandez R, McPherson G, Ramsay C, Cook J (2016) Automated imaging technologies for the diagnosis of glaucoma: a comparative diagnostic study for the evaluation of the diagnostic accuracy, performance as triage tests and cost-effectiveness (GATE study). Health Technol Assess 20:8CrossRef
17.
Zurück zum Zitat Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Buszewicz M, LiGHT Trial Study Group. (2019) Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet 393(10180):1505–1516CrossRef Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Buszewicz M, LiGHT Trial Study Group. (2019) Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet 393(10180):1505–1516CrossRef
19.
Zurück zum Zitat Khawaja AP, Campbell JH, Kirby N, Chandwani HS, Keyzor I, Parekh M, McNaught AI (2020) Real-world outcomes of selective laser Trabeculoplasty in the United Kingdom. UK glaucoma real-world data consortium. Ophthalmology 127(6):748–757CrossRef Khawaja AP, Campbell JH, Kirby N, Chandwani HS, Keyzor I, Parekh M, McNaught AI (2020) Real-world outcomes of selective laser Trabeculoplasty in the United Kingdom. UK glaucoma real-world data consortium. Ophthalmology 127(6):748–757CrossRef
20.
Zurück zum Zitat Gedde SJ, Schiffman JC, Feuer WJ, Parrish RK, Heuer DK, Brandt JD et al (2005) The tube versus trabeculectomy study: design and baseline characteristics of study patients. Am J Ophthalmol 140(2):275–287CrossRef Gedde SJ, Schiffman JC, Feuer WJ, Parrish RK, Heuer DK, Brandt JD et al (2005) The tube versus trabeculectomy study: design and baseline characteristics of study patients. Am J Ophthalmol 140(2):275–287CrossRef
21.
Zurück zum Zitat Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL et al (2009) Three-year follow-up of the tube versus trabeculectomy study. Am J Ophtalmol 148(5):670–684CrossRef Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL et al (2009) Three-year follow-up of the tube versus trabeculectomy study. Am J Ophtalmol 148(5):670–684CrossRef
22.
Zurück zum Zitat Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL et al (2012) Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Opthalmol 153(5):789–803CrossRef Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL et al (2012) Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Opthalmol 153(5):789–803CrossRef
23.
Zurück zum Zitat Gedde SJ, Feuer WJ, Shi W, Ahmed IIK, Brandt J (2018) Treatment outcomes in the primary tube versus trabeculectomy study after 1 year of follow-up. Am J Ophthalmol 125(5):650–663 Gedde SJ, Feuer WJ, Shi W, Ahmed IIK, Brandt J (2018) Treatment outcomes in the primary tube versus trabeculectomy study after 1 year of follow-up. Am J Ophthalmol 125(5):650–663
24.
Zurück zum Zitat Gedde SJ, Feuer WJ, Lim KS, Barton K, Goyal S, Ahmed IIK et al (2019) Treatment outcomes in the primary tube versus trabeculectomy study after 3 years of follow-up. Ophthalmology 127(3):333–345CrossRef Gedde SJ, Feuer WJ, Lim KS, Barton K, Goyal S, Ahmed IIK et al (2019) Treatment outcomes in the primary tube versus trabeculectomy study after 3 years of follow-up. Ophthalmology 127(3):333–345CrossRef
25.
Zurück zum Zitat A randomized study comparing the safety and efficacy of the InnFocus MicroShuntTM glaucoma drainage system to standard trabeculectomy in subjects with primary open angle glaucoma. ClinicalTrials.gov Identifier: NCT01881425 A randomized study comparing the safety and efficacy of the InnFocus MicroShuntTM glaucoma drainage system to standard trabeculectomy in subjects with primary open angle glaucoma. ClinicalTrials.gov Identifier: NCT01881425
26.
Zurück zum Zitat King AJ, Fernie G, Azuara-Blanco A, Burr JM, Garway-Heath D, Sparrow JM, Vale L, Hudson J, MacLennan G, McDonald A, Barton K, Norrie J (2017) Treatment of Advanced Glaucoma Study: a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy formpeople with newly diagnosed advanced glaucoma-study protocol. Br J Ophthalmol 102(7):922–928CrossRef King AJ, Fernie G, Azuara-Blanco A, Burr JM, Garway-Heath D, Sparrow JM, Vale L, Hudson J, MacLennan G, McDonald A, Barton K, Norrie J (2017) Treatment of Advanced Glaucoma Study: a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy formpeople with newly diagnosed advanced glaucoma-study protocol. Br J Ophthalmol 102(7):922–928CrossRef
Metadaten
Titel
Schlüsselstudien zum Glaukom der letzten 10 Jahre
verfasst von
Dr. Karl Mercieca, MD PGCMEd FRCOphth FEBOS-GL
Publikationsdatum
03.11.2021
Verlag
Springer Medizin
Erschienen in
Die Ophthalmologie / Ausgabe 12/2021
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI
https://doi.org/10.1007/s00347-021-01522-1

Weitere Artikel der Ausgabe 12/2021

Die Ophthalmologie 12/2021 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.